

# Supplementary Materials

**Table S1.** Primers used in this study.

<b>Genes</b>	<b>Forward Sequences</b>	<b>Reverse Sequences</b>
RIG-I	GTGCAAAGCCTTGGCATGT	TGGCTTGGGATGTGGTCTACTC
MDA5	GTTGAAAAGGCTGGCTGAAAAC	TCGATAACTCCTGAACCACTG
TLR3	CTCAGAAGATTACCAGCCGCC	CCATTATGAGACAGATCTAATG
TLR7	CACATACCAGACATCTCCCA	CCCAGTGAATAGGTACACAGTT
CXCL9	CCAGTAGTGAGAAAGGGTTCG	AGGGCTTGGGGCAAATTGTT
CXCL10	TGGCATTCAAGGAGTACCTCTC	CTTGATGGCCTTCGATTCTG
CXCL11	GACGCTGTCTTTGCATAGGC	GGATTTAGGCATCGTTGTCCTTT
IFIT2	GACACGGTTAAAGTGTGGAGG	TCCAGACGGTAGCTTGCTATT
IFIT3	AGAAAAGGTGACCTAGACAAAGC	CCTTGTAGCAGCACCCAATCT
MX1	GGTGGTCCCCAGTAATGTGG	CGTCAAGATTCCGATGGTCCT
ISG15	CGGGAACAAGTCCACGAA	CAACACTGGCTCTGGATGG
MX2	CAGAGGCAGCGGAATCGTAA	TGAAGCTCTAGCTCGGTGTTC
RSAD2	TTGGACATTCTCGCTATCTCCT	AGTGCTTTGATCTGTTCCGTC
IL-6	AGGAGACTTGCCTGGTGA	CAGGGGTGGTTATTGCATCT
IL-8	TTGGCAGCCTTCCTGATTTT	TCTTTAGCACTCCTTGGCAAAC
CCL5	CCTCATTGCTACTGCCCTCT	GGTGTGGTGTCCGAGGAATA
GAPDH	GCAAAGGCTGTGGGCAAGG	GGAGGAGTGGGTGTCGCTG
TNF- $\alpha$	ACGGCATGGATCTCAAAGACAACC	TGAGATAGCAAATCGGCTGACGGT
IFN- $\beta$	GCTTGGATTCTACAAAGAAGCA	ATAGATGGTCAATGCGGCGTC
GABRA1	AGCCGTCATTACAAGATGAACTT	TGGTCTCAGGCGATTGTCATAA
P2RY13	ATCGTGCTGTTAGGGCTCATA	CAAGATCGTATTTGGCAGGGAG
MC2R	GACTGTCTCGTGTGGTTTTG	GGCTGCCCAGCATATCAGAT
CHRNA2	CTCCTCTGTGCGCCATCCTCA	GGAAGGTCAGGTAAGTCTGAT
HRH2	CAGCAAGGGCAATCATAACCAC	GATCAGTAGCGGGAGGTAGAA
MS4A6A	TGTGGCATGATGGTATTGAGC	AGGGTCCTATGAATGGGTAAGC
OR2H2	CTTGTCTCTTACGGAGCCATTAC	TCTCTTGGGCATAGGGATTTTTG
XAF1	GCTCCACGAGTCTACTGTG	GTTCACTGCGACAGACATCTC
STAT1	CGGCTGAATTTTCGGCACCT	CAGTAACGATGAGAGGACCCT
FTMT	TGGAGTGTGCTCTACTCTTGG	ACGTGGTCACCTAGTTCTTTGA
GON4L	CTCAGGGAATCACCTACCTT	CTCAGGGAATCACCTACCTT
IL17A	TCCCACGAAATCCAGGATGC	GGATGTTGAGTTGACCATCAC
MKL2	TTATAGGCGTTGGGAAGGAGG	CCGGAGACAAAGCGTCACT
TNFSF10	TGCGTGCTGATCGTGATCTTC	GCTCGTTGGTAAAGTACACGTA

**Table S2.** Upregulated antiviral genes at 24 hpi.

<b>Gene Symbol</b>	<b>Fold Change</b>	<b><i>p</i>-Value</b>
RSAD2	30.71	8.20E-04
IFIT2	20.90	5.18E-03
IFIT3	20.53	4.96E-04
OASL	11.12	2.04E-03
MX2	10.97	2.62E-03
IFIT1	9.99	6.01E-04
DDX58	9.55	3.99E-02
OAS2	9.41	2.87E-03
IFI44L	7.73	3.79E-03
MX1	7.13	2.28E-03
OAS1	6.56	2.72E-03
IFIH1	5.12	1.57E-03
ISG15	4.46	1.82E-03
OAS3	4.05	2.02E-03
STAT1	3.97	3.06E-03
XAF1	3.82	1.09E-02
IFI6	3.79	4.38E-03
GBP1	3.60	2.54E-02
IFIT5	3.57	4.24E-03
DHX58	3.19	2.90E-03
IL29	3.17	2.84E-02
IFI27	3.13	3.65E-03
IFI35	2.92	4.53E-02
GBP4	2.90	1.10E-02
IFNB1	2.74	2.35E-02
IRF7	2.65	1.24E-02
ZBP1	2.60	5.87E-03
TAP1	2.41	4.00E-02
IFITM1	2.38	1.41E-02
TLR3	2.37	3.03E-02
IFI16	2.18	6.38E-03
MYD88	2.13	2.60E-03
ADAR	2.12	3.37E-03
STAT2	2.01	2.38E-03

**Table S3.**Co-upregulated genes among each time post-infection.

Gene Symbol	6 h		12 h		24 h	
	<i>p</i> -Value	Fold Change	<i>p</i> -Value	Fold Change	<i>p</i> -Value	Fold Change
MS4A6A	7.86E-03	5.28	9.80E-03	7.08	3.22E-03	2.57
TFF3	1.46E-02	4.51	3.67E-02	3.92	1.26E-02	3.05
ZG16	9.93E-03	3.66	7.51E-03	2.69	4.18E-02	2.77
MEP1A	7.00E-03	3.32	2.33E-02	2.23	1.30E-02	2.39
MAB21L3	1.97E-02	3.15	9.85E-03	3.46	2.82E-02	2.66
RFX4	2.07E-02	3.14	1.22E-02	3.75	3.78E-02	4.94
DEFB123	5.74E-03	2.86	1.73E-03	3.42	3.62E-02	4.34
POPDC2	4.28E-02	2.77	1.77E-03	3.08	1.99E-02	3.79
CDSN	3.27E-02	2.61	2.07E-03	3.46	6.29E-03	2.39
OR2H2	1.65E-02	2.27	1.27E-02	2.45	1.42E-02	4.92
ZFP57	1.81E-02	2.22	4.00E-02	4.23	2.11E-03	2.65
MUC5AC	1.85E-02	2.19	2.49E-02	2.10	1.58E-02	2.13
APOA5	5.41E-03	2.18	1.03E-02	2.41	9.82E-03	2.09
CD55	7.95E-03	2.14	9.78E-03	2.21	3.23E-02	2.23
RNF39	3.36E-02	2.11	3.51E-03	3.20	2.77E-02	2.66
GAL3ST2	2.54E-02	2.10	1.38E-02	3.28	1.46E-02	4.75
CSHL1	2.64E-03	2.07	5.84E-04	2.03	4.61E-02	2.51
MUC12	3.58E-02	2.04	2.54E-02	2.05	2.83E-02	3.71